China Universal Asset Management Co., Ltd. Ngm Biopharmaceuticals Inc Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$1.05 - $3.37 $1,094 - $3,511	1,042 Added 96.48%	2,122 $2,000
Q3 2023 Oct 30, 2023	BUY	$1.05 - $3.37 $1,094 - $3,511	1,042 Added 96.48%	2,122 $2,000
Q2 2023 May 21, 2024	SELL	$2.44 - $4.53 $78 - $144	-32 Reduced 2.88%	1,080 $2,000
Q2 2023 Jul 27, 2023	SELL	$2.44 - $4.53 $78 - $144	-32 Reduced 2.88%	1,080 $3,000
Q1 2023 May 21, 2024	BUY	$3.72 - $5.4 $1,049 - $1,522	282 Added 33.98%	1,112 $4,000
Q1 2023 Apr 27, 2023	BUY	$3.72 - $5.4 $1,049 - $1,522	282 Added 33.98%	1,112 $5,000
Q4 2022 May 21, 2024	BUY	$3.41 - $12.93 $2,830 - $10,731	830 New	830 $4,000
Q4 2022 Jan 31, 2023	BUY	$3.41 - $12.93 $265 - $1,008	78 Added 10.37%	830 $4,000
Q3 2022 Oct 21, 2022	BUY	$12.59 - $17.67 $9,467 - $13,287	752 New	752 $10,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account